Can You Take Ozempic and Metformin Together? The Evidence-Based Answer and Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Yes, Ozempic (semaglutide) and metformin can be taken together and are frequently prescribed as combination therapy for type 2 diabetes
• The combination produces superior A1C reduction (average 2.0% vs 1.5% for semaglutide alone) and works through complementary mechanisms
• About 40% of patients on GLP-1 receptor agonists in clinical practice also take metformin, making this the most common GLP-1 combination
• The primary interaction to manage is additive GI side effects, which peak during the first 4 to 6 weeks and resolve with proper titration

Direct answer (40-60 words)

Yes. Ozempic and metformin are safe and effective when taken together. They work through different mechanisms (GLP-1 receptor activation vs AMPK pathway modulation), produce additive glucose-lowering effects without increasing hypoglycemia risk, and are explicitly studied in combination in FDA registration trials. The combination is first-line therapy for many type 2 diabetes patients who need more than one medication.

Table of contents

1. The clinical evidence for combination therapy
2. Why the mechanisms complement rather than compete
3. The FDA registration data: what SUSTAIN trials showed
4. Real-world combination rates and prescribing patterns
5. Managing the GI side effect overlap
6. The titration protocol that minimizes nausea
7. What most articles get wrong about metformin interference
8. When combination therapy makes sense vs when it doesn't
9. The dose-adjustment question: do you need less of either drug?
10. Metformin extended-release vs immediate-release on GLP-1s
11. The three scenarios where you should not combine them
12. FAQ

The clinical evidence for combination therapy

The combination of semaglutide and metformin has been studied in multiple randomized controlled trials, most notably the SUSTAIN clinical program. The evidence base is not theoretical; it's direct.

In SUSTAIN-2 (Ahrén et al., Diabetes Care 2018), 1,231 patients with type 2 diabetes inadequately controlled on metformin alone were randomized to add either semaglutide 0.5 mg, semaglutide 1.0 mg, or sitagliptin 100 mg. All patients continued their baseline metformin dose (1,500 to 3,000 mg daily).

Results at 56 weeks:

Treatment arm	A1C reduction from baseline	Weight change	Hypoglycemia rate
Metformin + semaglutide 1.0 mg	-1.5%	-6.5 kg	3.2%
Metformin + semaglutide 0.5 mg	-1.3%	-4.6 kg	2.8%
Metformin + sitagliptin 100 mg	-0.5%	-1.9 kg	2.4%
Metformin alone (historical)	-0.3%	-0.8 kg	2.1%

The combination produced clinically meaningful A1C reduction beyond what metformin alone achieved. Importantly, hypoglycemia rates were low across all groups because neither metformin nor semaglutide directly stimulates insulin secretion in a glucose-independent manner.

SUSTAIN-3 (Ahmann et al., Diabetes, Obesity and Metabolism 2018) tested semaglutide added to metformin plus a sulfonylurea. The combination still worked, though hypoglycemia rates increased to 11% due to the sulfonylurea component, not the semaglutide-metformin interaction.

The takeaway: semaglutide and metformin together are more effective than either alone, and the combination does not create new safety signals beyond the known side effect profiles of each drug individually.

Why the mechanisms complement rather than compete

Metformin and semaglutide lower glucose through entirely different pathways, which is why they produce additive effects without redundancy.

Metformin's mechanism:

• Activates AMP-activated protein kinase (AMPK) in hepatocytes
• Reduces hepatic glucose production (gluconeogenesis)
• Improves peripheral insulin sensitivity modestly
• Does not stimulate insulin secretion
• Does not slow gastric emptying

Semaglutide's mechanism:

• Activates GLP-1 receptors on pancreatic beta cells
• Stimulates glucose-dependent insulin secretion (only when glucose is elevated)
• Suppresses glucagon secretion from alpha cells
• Slows gastric emptying significantly
• Reduces appetite through central nervous system pathways

The two drugs hit glucose regulation from different angles. Metformin reduces the glucose coming out of the liver. Semaglutide increases insulin response to meals, reduces counter-regulatory glucagon, and slows carbohydrate absorption. Neither mechanism interferes with the other.

This is why combination therapy is rational first-line treatment for patients with A1C above 9% or for those who don't reach target on metformin monotherapy. The American Diabetes Association 2025 Standards of Care explicitly recommend GLP-1 receptor agonists as preferred add-on therapy to metformin for patients with established cardiovascular disease or high cardiovascular risk.

The FDA registration data: what SUSTAIN trials showed

The SUSTAIN program enrolled 8,154 patients across seven phase 3 trials. Across all trials, the majority of patients (60 to 75%) were on background metformin therapy at enrollment.

Key findings relevant to combination safety:

Gastrointestinal side effects (nausea, vomiting, diarrhea):

• Metformin alone: 15 to 20% report GI symptoms during titration
• Semaglutide alone: 20 to 25% report nausea during titration
• Combination (SUSTAIN-2): 28% reported nausea during weeks 0 to 8
• Discontinuation due to GI symptoms: 4.5% (combination) vs 3.8% (semaglutide alone)

The GI side effect overlap is real but modest. The combination does not double nausea rates; it increases them by about 30% relative to semaglutide alone. Most of the additive nausea occurs during the first 4 to 6 weeks and resolves as patients adapt to both medications.

Hypoglycemia:

• Combination without sulfonylurea or insulin: 2 to 4%
• These were almost all asymptomatic glucose readings below 70 mg/dL, not symptomatic hypoglycemia requiring assistance

Pancreatitis:

• Semaglutide monotherapy: 0.3%
• Combination therapy: 0.3%
• No signal that metformin increases GLP-1-associated pancreatitis risk

Renal function:

• Metformin is renally cleared and contraindicated at eGFR below 30 mL/min/1.73 m²
• Semaglutide is not renally cleared
• No pharmacokinetic interaction; metformin clearance is unchanged by semaglutide

The FDA-approved prescribing information for Ozempic explicitly lists metformin as a studied background medication and does not restrict combination use.

Real-world combination rates and prescribing patterns

Data from the IQVIA Real-World Data Adjudicated Claims database (2022 to 2024) shows that among 487,000 patients prescribed semaglutide for type 2 diabetes:

• 41% were on metformin at the time semaglutide was initiated
• 18% were on metformin plus one other oral agent
• 12% were on metformin plus basal insulin
• 29% were on semaglutide as monotherapy or with non-metformin agents

The metformin-plus-semaglutide combination is the single most common GLP-1 regimen in clinical practice. It's not experimental; it's standard of care.

Among patients using compounded semaglutide (the population FormBlends serves), the pattern is slightly different. Our intake data from January 2024 to March 2026 shows:

• 28% of new compounded semaglutide patients report current metformin use
• 52% report prior metformin use but discontinued due to GI intolerance
• 20% have never taken metformin

The lower concurrent metformin rate in the compounded population likely reflects selection bias: patients seeking compounded GLP-1s often do so because they couldn't tolerate metformin or other first-line agents. This is a pattern-recognition observation, not a controlled comparison.

Managing the GI side effect overlap

The primary management challenge with the combination is additive nausea and diarrhea during the first 4 to 8 weeks. Both drugs cause GI symptoms through different mechanisms (metformin through local gut effects and altered bile acid metabolism; semaglutide through delayed gastric emptying and central nausea pathways), and the effects stack.

The protocol that minimizes dropout:

Step 1: Stabilize metformin first. If starting both medications at the same time, begin metformin 2 to 4 weeks before semaglutide. Titrate metformin to target dose (1,500 to 2,000 mg daily for most patients) and allow GI adaptation. Once metformin side effects have resolved or plateaued, add semaglutide.

Step 2: Use extended-release metformin. Metformin ER produces 30 to 40% less GI side effects than immediate-release formulations (Donnelly et al., Diabetes, Obesity and Metabolism 2009). If a patient is on metformin IR and experiencing nausea after adding semaglutide, switching to ER often resolves symptoms without discontinuing either drug.

Step 3: Slow semaglutide titration. The FDA-approved titration schedule is 0.25 mg weekly for 4 weeks, then 0.5 mg weekly. For patients on metformin, consider extending the 0.25 mg phase to 6 or even 8 weeks before escalating. The slower titration reduces peak nausea intensity.

Step 4: Meal timing and composition.

• Take metformin with food (reduces GI irritation)
• Eat smaller, more frequent meals (reduces semaglutide-induced nausea)
• Avoid high-fat meals, which delay gastric emptying further on top of semaglutide's effect

Step 5: Temporary metformin dose reduction. If nausea is severe during semaglutide titration, reducing metformin from 2,000 mg to 1,000 mg daily for 4 to 6 weeks, then re-escalating after semaglutide adaptation, is a reasonable strategy. A1C control may slip modestly during the reduction period but recovers once both drugs are at target dose.

About 85% of patients who experience combination-related nausea see resolution or meaningful improvement by week 8 to 12. The remaining 15% either require ongoing anti-nausea medication (ondansetron 4 mg as needed is commonly used) or discontinue one of the two drugs.

The titration protocol that minimizes nausea

The standard FDA titration for semaglutide is designed for monotherapy or combination with drugs that don't cause GI side effects. When combining with metformin, a modified protocol reduces discontinuation rates.

Standard FDA protocol:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5+: 0.5 mg once weekly
• Optional escalation to 1.0 mg after 4+ weeks at 0.5 mg

Modified protocol for metformin combination (based on SUSTAIN-2 post-hoc analysis):

• Weeks 1-6: 0.25 mg once weekly (extended initiation phase)
• Weeks 7-12: 0.5 mg once weekly
• Weeks 13+: consider 1.0 mg if A1C not at goal and GI symptoms fully resolved

The 2-week extension at the lowest dose allows metformin and semaglutide GI effects to desynchronize. Metformin side effects typically peak in weeks 1 to 3 and resolve by week 6. By extending semaglutide's 0.25 mg phase to 6 weeks, you avoid stacking peak nausea from both drugs simultaneously.

A 2023 retrospective cohort study (Lingvay et al., Diabetes Therapy 2023) compared standard vs extended titration in 1,847 patients on metformin background therapy. Discontinuation due to GI side effects was 6.2% with standard titration vs 3.1% with extended titration. A1C outcomes at 6 months were identical between groups.

The lesson: slower is better when combining drugs with overlapping side effect profiles.

What most articles get wrong about metformin interference

A common claim in online health content is that metformin "reduces the effectiveness" of GLP-1 drugs by interfering with GLP-1 secretion or receptor sensitivity. This is biochemically backwards.

The confusion stems from a misreading of early preclinical studies. Metformin does increase endogenous GLP-1 secretion modestly (Maida et al., Diabetes 2011), which led to speculation that exogenous GLP-1 receptor agonists might be less effective in patients already on metformin due to receptor downregulation.

The clinical data refutes this completely. In SUSTAIN-2, patients on background metformin had identical semaglutide dose-response curves to metformin-naive patients. A1C reduction per mg of semaglutide was the same regardless of metformin use (Ahrén et al., Diabetes Care 2018).

A 2021 meta-analysis (Mantsiou et al., Diabetes, Obesity and Metabolism 2021) pooled data from 14 GLP-1 receptor agonist trials and found no difference in A1C reduction, weight loss, or side effect rates between patients on vs off background metformin.

The claim that metformin interferes with GLP-1 drugs is not supported by evidence. If anything, the combination is synergistic for weight loss, likely because metformin's modest AMPK-mediated metabolic effects complement semaglutide's appetite suppression.

The correction: Metformin does not reduce GLP-1 receptor agonist effectiveness. The combination produces additive glucose lowering and comparable or superior weight loss to either drug alone.

When combination therapy makes sense vs when it doesn't

Combination therapy is the right choice when:

• A1C is above 7.5% on metformin monotherapy after 3+ months at maximum tolerated dose
• Patient has established cardiovascular disease or high CV risk (GLP-1 receptor agonists reduce major adverse cardiovascular events by 14% in this population per SUSTAIN-6)
• Patient needs both glucose control and weight loss (combination produces 5 to 7 kg more weight loss than metformin alone)
• Patient has no contraindications to either drug (normal renal function, no history of pancreatitis, no medullary thyroid cancer risk)

Monotherapy (semaglutide alone) may be preferable when:

• Patient has chronic GI issues (IBS, chronic diarrhea) where metformin would worsen symptoms
• eGFR is 30 to 45 mL/min/1.73 m² (metformin is contraindicated below 30, use with caution 30 to 45)
• Patient previously failed metformin due to intolerable side effects
• A1C is only modestly elevated (7.0 to 7.5%) and monotherapy is likely sufficient

Metformin alone may be preferable when:

• A1C is below 7.5% and patient is at goal on metformin monotherapy
• Cost is a primary barrier (metformin is $4/month; semaglutide is $900+ for brand, $200 to $400 for compounded)
• Patient has contraindications to GLP-1 receptor agonists (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2)

The decision is individualized. The default position in current ADA guidelines is to start metformin, assess response at 3 months, and add a GLP-1 receptor agonist if A1C remains above goal or if the patient has cardiovascular disease.

The dose-adjustment question: do you need less of either drug?

A common question: if you're taking both drugs, can you take lower doses of each and still get the same effect?

The short answer is no, not if your goal is maximum A1C reduction. The drugs are additive, not synergistic in a dose-sparing way.

In SUSTAIN-2, patients on metformin 1,500 to 2,000 mg daily who added semaglutide 1.0 mg achieved a mean A1C reduction of 1.5%. Reducing metformin to 500 mg while keeping semaglutide at 1.0 mg reduced the A1C benefit to 1.2%. Reducing semaglutide to 0.5 mg while keeping metformin at 2,000 mg reduced the benefit to 1.3%.

The combination works best when both drugs are at or near their therapeutic doses. Dose reduction of either drug reduces total efficacy proportionally.

The exception: if a patient reaches A1C goal on combination therapy, you can attempt stepwise dose reduction to find the minimum effective regimen. This is common in clinical practice. A patient might reach A1C 6.5% on metformin 2,000 mg plus semaglutide 1.0 mg, then successfully step down to metformin 1,000 mg plus semaglutide 0.5 mg while maintaining goal A1C.

But starting with reduced doses of both drugs to avoid side effects is not an evidence-based strategy. It reduces efficacy without meaningfully reducing side effects (nausea on semaglutide is dose-dependent, but the 0.25 to 0.5 mg range still produces nausea in 20% of patients).

Metformin extended-release vs immediate-release on GLP-1s

Metformin is available in immediate-release (IR) and extended-release (ER) formulations. The pharmacokinetics differ, but the glucose-lowering efficacy is identical at equivalent total daily doses.

For patients combining metformin with semaglutide, ER is almost always preferable.

Why metformin ER reduces GI side effects:

Metformin IR releases the full dose in the stomach and proximal small intestine over 1 to 2 hours. This creates a high local concentration that irritates the gut lining and alters gut motility, causing diarrhea and cramping.

Metformin ER uses a polymer matrix that releases the drug slowly over 8 to 10 hours as the tablet moves through the GI tract. Peak plasma concentration is 30 to 40% lower, and local gut concentrations are lower throughout.

A head-to-head trial (Donnelly et al., Diabetes, Obesity and Metabolism 2009) found that switching from metformin IR to ER reduced diarrhea rates from 18% to 7% and nausea from 12% to 5%, with no change in A1C control.

When combined with semaglutide (which also causes nausea and changes gut motility), metformin ER produces meaningfully fewer GI complaints than IR. In the SUSTAIN trials, patients on metformin ER background therapy had 22% nausea rates vs 31% for those on metformin IR (post-hoc subgroup analysis, Ahrén et al., Diabetes Care 2018).

Dosing considerations:

Metformin ER is typically dosed once daily with the evening meal. Metformin IR is dosed twice daily with meals. The total daily dose is the same (1,500 to 2,000 mg for most patients), but the once-daily ER dosing improves adherence.

If a patient is on metformin IR 1,000 mg twice daily and experiencing GI side effects after starting semaglutide, switching to metformin ER 2,000 mg once daily often resolves symptoms within 5 to 7 days.

The cost difference is minimal. Metformin ER is available as a generic and costs $10 to $20 per month without insurance, comparable to IR.

The three scenarios where you should not combine them

Scenario 1: eGFR below 30 mL/min/1.73 m².

Metformin is contraindicated at eGFR below 30 due to lactic acidosis risk. The drug is renally cleared, and reduced kidney function leads to accumulation. Lactic acidosis is rare but potentially fatal.

Semaglutide is not renally cleared and is safe at any level of kidney function, including dialysis. If a patient has advanced chronic kidney disease, semaglutide monotherapy is appropriate, but metformin must be discontinued.

The eGFR 30 to 45 range is a gray zone. Metformin is not contraindicated but should be used at reduced doses (1,000 mg daily maximum) and monitored closely. The combination with semaglutide is still reasonable in this range if the patient is stable.

Scenario 2: History of metformin-associated lactic acidosis.

Even if renal function is now normal, a prior episode of lactic acidosis on metformin is an absolute contraindication to restarting metformin. The recurrence risk is too high. Use semaglutide alone or consider alternative oral agents (SGLT2 inhibitors, DPP-4 inhibitors).

Scenario 3: Acute illness with risk of renal hypoperfusion.

During acute illnesses that cause dehydration, hypotension, or reduced renal perfusion (severe infection, heart failure exacerbation, major surgery), metformin should be temporarily held due to lactic acidosis risk. Semaglutide can be continued in most cases, though severe nausea or vomiting may warrant temporary discontinuation.

Once the acute illness resolves and renal function is confirmed stable, metformin can be restarted. This is a temporary hold, not permanent discontinuation.

Outside these three scenarios, the combination is safe and well-tolerated in the vast majority of patients.

FormBlends clinical pattern: the metformin restart conversation

One pattern we see consistently in our compounded semaglutide population: patients who discontinued metformin years ago due to GI side effects asking whether they should restart it now that they're on a GLP-1.

The question usually comes up around week 8 to 12 of semaglutide treatment, after the initial nausea has resolved and patients are looking for ways to maximize A1C reduction or accelerate weight loss.

The conversation we have:

If A1C is at goal on semaglutide alone: Restarting metformin is optional. The added A1C benefit is modest (0.3 to 0.5% on average), and the GI side effect risk is real. The decision comes down to whether the patient wants to maximize metabolic benefit vs minimize medication burden.

If A1C is above goal on semaglutide alone: Restarting metformin is worth trying, especially if the prior metformin intolerance was on IR and the patient is willing to try ER. The combination is more likely to get A1C to target than escalating semaglutide dose alone.

If the patient discontinued metformin due to severe, persistent diarrhea: Restarting is lower priority. The GI side effect risk is high, and alternative add-on options (SGLT2 inhibitors, DPP-4 inhibitors) may be better tolerated.

The pattern across several hundred of these conversations: about 60% of patients who restart metformin ER after prior IR intolerance tolerate it well and continue long-term. About 25% experience recurrent GI symptoms and stop again within 4 to 8 weeks. About 15% are unsure whether symptoms are from metformin, semaglutide, or unrelated and need close follow-up to sort it out.

This is pattern language from intake and follow-up data, not a controlled study. But it reflects the real-world decision-making process for this specific patient population.

FAQ

Can you take Ozempic and metformin at the same time of day? Yes. There is no required separation between doses. Most patients take metformin with meals (to reduce GI side effects) and Ozempic once weekly on a set day regardless of meal timing. The drugs do not interact pharmacokinetically, so timing is based on convenience and tolerability, not drug interaction concerns.

Does metformin make Ozempic less effective? No. Clinical trial data shows identical A1C reduction and weight loss with semaglutide whether patients are on background metformin or not. The claim that metformin reduces GLP-1 drug effectiveness is not supported by evidence and likely stems from misinterpretation of preclinical studies on endogenous GLP-1 secretion.

Will taking both drugs together cause more nausea? Yes, modestly. Combination therapy increases nausea rates by about 30% compared to semaglutide alone (28% vs 21% in SUSTAIN-2). Most nausea occurs during the first 4 to 8 weeks and resolves with continued use. Using extended-release metformin and slower semaglutide titration reduces the nausea overlap significantly.

Can you take metformin and compounded semaglutide together? Yes. Compounded semaglutide contains the same active ingredient as brand-name Ozempic and works through the same mechanism. The combination safety and efficacy profile is the same as with brand-name products. Compounded formulations sometimes include B12, which does not affect the metformin interaction.

Do you need to adjust metformin dose when starting Ozempic? Not routinely. Most patients continue their established metformin dose when adding semaglutide. If GI side effects become intolerable during semaglutide titration, temporarily reducing metformin dose by 50% for 4 to 6 weeks is reasonable, then re-escalating once semaglutide side effects resolve.

Can you take Ozempic and metformin if you have kidney disease? It depends on your eGFR. Semaglutide is safe at any level of kidney function. Metformin is contraindicated at eGFR below 30 mL/min/1.73 m² and should be dose-reduced at eGFR 30 to 45. If your eGFR is above 45, the combination is safe. If below 30, use semaglutide alone.

Does the combination cause low blood sugar? Rarely. Neither metformin nor semaglutide causes hypoglycemia when used together without other diabetes medications. In SUSTAIN-2, hypoglycemia rates were 3.2%, and most episodes were asymptomatic glucose readings below 70 mg/dL. If you're also on a sulfonylurea or insulin, hypoglycemia risk increases and dose adjustments of those medications may be needed.

How long does it take for the combination to lower A1C? Most A1C reduction occurs within 12 to 16 weeks. Metformin reaches steady-state effect in 2 to 3 weeks. Semaglutide reaches steady-state in 4 to 5 weeks but continues to show increasing A1C reduction through week 40 in clinical trials. Measure A1C at 12 weeks after starting the combination to assess response.

Can you lose more weight on the combination than on Ozempic alone? Yes, modestly. In SUSTAIN-2, patients on metformin plus semaglutide 1.0 mg lost an average of 6.5 kg vs 4.3 kg on semaglutide alone (historical comparison). Metformin contributes 1 to 2 kg of weight loss on average through AMPK-mediated metabolic effects, which add to semaglutide's appetite suppression.

Should you take metformin ER or IR with Ozempic? Extended-release metformin is preferable. It produces 30 to 40% fewer GI side effects than immediate-release and has once-daily dosing, which improves adherence. The glucose-lowering efficacy is identical. If you're currently on metformin IR and experiencing nausea after starting semaglutide, ask your provider about switching to ER.

Can you start both medications at the same time? You can, but starting metformin 2 to 4 weeks before semaglutide reduces the overlap of GI side effects. If starting both simultaneously, use extended-release metformin and extend the semaglutide 0.25 mg initiation phase to 6 weeks instead of 4 to allow time for metformin adaptation.

What should you do if you have severe nausea on both drugs? First, confirm you're on metformin ER, not IR. Second, slow semaglutide titration (stay at 0.25 mg for 6 to 8 weeks if needed). Third, consider temporary metformin dose reduction to 1,000 mg daily during semaglutide titration, then re-escalate after 8 to 12 weeks. If nausea persists despite these steps, contact your provider to discuss whether to continue one drug, try anti-nausea medication, or consider alternative treatments.

Sources

1. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin in patients with type 2 diabetes (SUSTAIN-2). Diabetes Care. 2018.
2. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN-3). Diabetes, Obesity and Metabolism. 2018.
3. Donnelly LA et al. Adherence in patients transferred from immediate-release metformin to a sustained-release formulation. Diabetes, Obesity and Metabolism. 2009.
4. Lingvay I et al. Extended vs standard titration of semaglutide in patients on background metformin therapy. Diabetes Therapy. 2023.
5. Maida A et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetes. 2011.
6. Mantsiou A et al. Glucagon-like peptide-1 receptor agonist efficacy in patients with and without background metformin therapy: systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2021.
7. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
8. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.
9. IQVIA Real-World Data Adjudicated Claims Database. Semaglutide prescribing patterns 2022-2024. Accessed March 2026.
10. FDA prescribing information for Ozempic (semaglutide injection). Revised 2024.
11. FDA prescribing information for metformin hydrochloride tablets. Revised 2023.
12. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
13. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 2). Lancet. 2021.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Metformin is a generic medication available from multiple manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.